BACKGROUND
Graves’ disease is the most common cause of hyperthyroidism in the United States. Graves’ disease is caused by antibodies to the TSH receptor (TRAb) that attack and turn on the thyroid, causing the gland to become hyperthyroid. Symptoms of Graves’ disease include weight loss, heat intolerance, insomnia, increased frequency of bowel movements, palpitations and tremors. Graves’ disease is treated with antithyroid medications, mainly methimazole. The goal of treatment with methimazole is for Graves’ disease to have the antibodies to go away and for the disease to go into remission. Patients are usually treated for 12–18 months before stopping the antithyroid medication to determine if the Grave’ disease is in remission. However, response to antithyroid medications is variable. Some patients will likely achieve remission within the first 6–12 months; some will never achieve remission. Thus, not all patients will need to be treated for the same period of tim.

Studies have suggested that level of TRAb at the diagnosis of Graves’ disease can help predict the likelihood of remission or recurrence, with lower levels of TRAb increasing the likelihood of remission. This study evaluated whether less than 12 months of treatment could be as effective as standard-duration therapy in patients with low levels of TRAb in patients with Graves’ disease.

THE FULL ARTICLE TITLE
Razvi S, et al. Shorter versus standard antithyroid drug therapy in Graves’ disease with lower baseline thyrotropin receptor antibody (TRAb) levels: relapse outcomes from a propensity-weighted analysis. Thyroid 2026;36(9):961– 969; doi: 10.1177/10507256261470303. PMID: 42478510.

SUMMARY OF THE STUDY
This was a study of 369 adults with newly diagnosed Graves’ disease and lower baseline thyrotropin receptor antibody (TRAb) levels. All patients were treated with antithyroid medications. Patients were divided by total antithyroid medications treatment duration: a shortduration group (<12 months; 134 patients) and a standard- duration group (12–18 months; 235 patients). The average of patients was 46 years, 82% were female and the average follow-up was 58 months.

The authors noted a relapse rate of 17.2% for those with less than 12-month use of antithyroid medication versus 20.4% relapse rate in those receiving the 12–18 months course of antithyroid medication. However, after adjusting for differences, both groups were nearly identical for the relapse risk, but favorable for the group with a shorter course of antithyroid medication.

WHAT ARE THE IMPLICATIONS OF THIS STUDY?
This study suggests that patients with Graves’ disease who have lower baseline TRAb levels will likely benefit from a shorter antithyroid drug course. The results suggest that antithyroid drug therapy treatment could decrease from an average of 18 months to <12 months in these patients with lower TRAb levels. Thus, the authors noted the importance of individualizing Graves’ disease management and advocate for more research on early antibody markers and their role in remission and relapse rates.

— Joanna Miragaya, MD

Table of Contents | PDF File for Saving and Printing